Table 1.
Baseline characteristics of the 780 Swedish patients according to randomization group
| Characteristic | Treatment group, no. (%) | |
|---|---|---|
| Experimental group (tailored dose-dense chemotherapy) n = 384 |
Standard group (standard chemotherapy) n = 396 |
|
| Age, median [min–max] | 51.9 [24.7–64.8] | 50.0 [21.4–65.9] |
| Type of surgery | ||
| Mastectomy | 234 (61) | 237 (60) |
| Breast-conserving surgery | 150 (39) | 150 (40) |
| Tumour size, cm | ||
| ≤ 2 | 158 (41) | 158 (40) |
| > 2 to 5 | 196 (51) | 215 (54) |
| > 5 | 30 (8) | 23 (6) |
| Positive nodes, no. | ||
| 0 | 22 (6) | 17 (4) |
| 1–3 | 236 (62) | 233 (59) |
| 4–9 | 87 (23) | 110 (28) |
| > 9 | 39 (10) | 36 (9) |
| Tumour grade | ||
| 1 | 29 (8) | 24 (6) |
| 2 | 151 (39) | 171 (43) |
| 3 | 201 (52) | 201 (51) |
| Missing | 3 (1) | 0 (0) |
| Hormone receptor status | ||
| ER or PR positive | 297 (77) | 298 (75) |
| ER and PR negative | 86 (23) | 98 (25) |
| Missing | 1 (0) | 0 (0) |
| HER2 status | ||
| Negative | 313 (82) | 312 (79) |
| Positive | 71 (19) | 84 (21) |
| Ki-67 positive cells, IHC | ||
| ≤20 | 150 (39) | 155 (39) |
| > 20 | 197 (51) | 200 (51) |
| Missing | 37 (10) | 41 (10) |